Aligos’s THRβ agonist yielded hepatic fat reduction equal to or better than its class, but the biotech prefers moving forward with a partner. Hepatitis B may be the firm’s higher priority.

Leaders from Eli Lilly and Vertex Pharmaceuticals, 9amHealth, Features Capital, and accelerator PharmStars discussed the convergence of biopharma, medtech and healthtech, and what is needed to achieve health care transformation, in an LSX World Congress USA panel.

The company said the CENTERSTONE study marked the first time a global Phase III trial showed reduced transmission of influenza.

The Barcelona meeting saw early data from two candidates from Incyte and Pfizer which suggest some progress for a new drug mechanism that has so far underwhelmed.